Biogen Financial Statements From 2010 to 2024
| IDP Stock | EUR 147.30 0.80 0.54% |
Check Biogen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biogen's main balance sheet or income statement drivers, such as , as well as many indicators such as . Biogen financial statements analysis is a perfect complement when working with Biogen Valuation or Volatility modules.
Biogen |
Biogen Inc Company Profit Margin Analysis
Biogen's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Biogen Profit Margin | 0.30 % |
Most of Biogen's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biogen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Biogen Inc has a Profit Margin of 0.2995%. This is 102.67% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The profit margin for all Germany stocks is 123.58% lower than that of the firm.
Biogen Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biogen's current stock value. Our valuation model uses many indicators to compare Biogen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biogen competition to find correlations between indicators driving Biogen's intrinsic value. More Info.Biogen Inc is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.32 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biogen Inc is roughly 3.13 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biogen's earnings, one of the primary drivers of an investment's value.About Biogen Financial Statements
Biogen stakeholders use historical fundamental indicators, such as Biogen's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biogen investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biogen's assets and liabilities are reflected in the revenues and expenses on Biogen's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biogen Inc. Please read more on our technical analysis and fundamental analysis pages.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. BIOGEN INC operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 9100 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Biogen Stock
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out the analysis of Biogen Correlation against competitors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.